Generex
Biotechnology Begins Testing New Vaccine for Breast Cancer Patients...(GNBT)
Generex
Biotechnology Receives Australian Patent for Novel Vaccine Technology...(GNBT)
CyberGuard
Selects DirectView to Implement Global Videoconferencing Systems...(DRVW)
Surge
in Consumer Spending Boosts Wal-Mart Mexico...(BIOHF)
TelePlus
Reports Preliminary Q1 Revenues of U.S. $2.96 Million, 24% Gain Over Last Year...(TLPE)
TelePlus
Provides Update to Investors on Recent Acquisitions...(TLPE)
Generex Biotechnology...(GNBT)
Press Release: Generex
Biotechnology Begins Testing New Vaccine for Breast Cancer Patients Phase
I Trial With Walter Reed Army Medical Center Will Measure Immune Responses as
Well as Safety The
compound, AE37, is designed to stimulate an immune response against the
tumor-causing gene HER-2/neu, which occurs in a significant percentage of
patients with breast cancer as well as other cancers. A robust immune response
against HER-2/neu has the potential to destroy tumor cells even at sites in the
body distant from the primary tumor. To view the
Full Press Release please visit http://biz.yahoo.com/prnews/050428/nyth064.html?.v=10
Press Release:
Generex
Biotechnology Receives Australian Patent for Novel Vaccine Technology
Announced that its
wholly owned subsidiary, Antigen Express, has received Australian Patent No.
778115 titled "Hybrid Peptides Modulate the Immune Response." Antigen
Express is designing and testing such vaccine peptides for the control of cancer
and infectious diseases with a particular focus on the pandemic H5N1 influenza,
which has been reported in South East Asia.
To view the
Full Press Release please visit http://biz.yahoo.com/prnews/050426/nytu053.html?.v=5
For the Full Profile on GNBT please visit http://www.smallcapreview.com/gnbt.htm
DirectView...(DRVW)
Press Release: CyberGuard
Selects DirectView to Implement Global Videoconferencing Systems
Announced it has been selected by
CyberGuard Corporation (Nasdaq: CGFW) to implement its global video conferencing
infrastructure. CyberGuard, a global provider of security solutions that protect
the business-critical information assets of Global 2000 enterprises and
government organizations, will use the system to link its global headquarters in
Florida with regional headquarters locations in Germany, London, Hungary, and
Australia. To view the Full
Press Release please visit http://biz.yahoo.com/pz/050420/76651.html
For the Full Profile on DRVW please visit http://www.smallcapreview.com/drvw.htm
Biotech Holdings...(BIOHF)
Press Release: Surge
in Consumer Spending Boosts Wal-Mart Mexico
Biotech Holdings Ltd., a
Canadian-based pharmaceutical manufacturer, announced Wednesday that the company
had received its second order from Wal-Mart de Mexico SA for its diabetic drug,
Sucanon.
According to Robert B. Rieveley,
Biotech Holdings President, the order announced today marks the 137th Wal-Mart
store in Mexico that now stocks the company's diabetic drug.
Rieveley noted that drugstore
chains Farmacia Benavides, Nutrimania and Farmacia Paris also buy Biotech
Holdings' diabetic drug. Rieveley said that his company now served over 600
stores in Mexico.
To view the Full
Press Release please visit http://biz.yahoo.com/iw/050428/085573.html
TelePlus Enterprises...(TLPE)
Press Release: TelePlus
Reports Preliminary Q1 Revenues of U.S. $2.96 Million, 24% Gain Over Last Year ``Our
first quarter results reflect a continued strong performance from our
operations,'' stated company CEO Marius Silvasan. ``We are further pleased that
these results were achieved without the impact of the Keda and Freedom
acquisitions. These acquisitions will impact the results in the next quarter.'' To view the Full
Press Release please visit http://biz.yahoo.com/pz/050427/77021.html
Press Release:
TelePlus
Provides Update to Investors on Recent Acquisitions
Since last December,
TelePlus has signed and executed definitive agreements with 5 companies (Keda
Consulting, Inc., Freedom Phone Lines, Telizon Inc., Canada Reconnect, Inc., and
Avenue Reconnect, Inc.).
The acquired
companies provide local, long distance and Internet prepaid services primarily
to residential customers (except for Telizon which provides services to business
users) across Canada. Total number of combined users of the target companies
exceeds 29,300.
To view the Full
Press Release please visit http://biz.yahoo.com/pz/050425/76804.html
For the Full Profile on TLPE please visit http://www.smallcapreview.com/tlpe.htm
Disclaimer
SmallCapReview.com
feature stock reports are intended to be stock ideas, NOT recommendations.
Please do your own research before investing. It is crucial that you at least
look at current SEC filings and read the latest press releases. For
continuing coverage of GNBT, DRVW and TLPE please sign up for our free newsletter,
SmallCapReview.com
News. Information contained in this report was extracted from current documents
filed with the SEC, the company web site and other publicly available sources
deemed reliable. For more information see our disclaimer section, a link of
which can be found on our web site. This document contains forward-looking
statements, particularly as related to the business plans of the Company, within
the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the
Securities Exchange Act of 1934, and are subject to the safe harbor created by
these sections. Actual results may differ materially from the Company's
expectations and estimates. The information provided in this report is not
intended for distribution to, or use by, any person or entity in any
jurisdiction or country where such distribution or use would be contrary to law
or regulation or which would subject us to any registration requirement within
such jurisdiction or country.
Copyright
SmallCapReview.com. All rights reserved. SmallCapReview.com is not a Registered
Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All
materials presented on our web site and individual reports released to the
public through this web site, e-mail or any other means of transmission are not
to be regarded as investment advice and are only for informative purposes.
Before making a purchase or sale of any securities featured on our web site
or mentioned in our reports, we strongly encourage and recommend consultation
with a registered securities representative. This is not to be construed as
a solicitation or recommendation to buy or sell securities. As with any stock,
companies we select to profile involve a degree of investment risk and
volatility. Particularly Small-Caps and OTC-BB stocks. All investors are
cautioned that they may lose all or a portion of their investment if they decide
to make a purchase in any of our profiled companies. Past performance of our
profiled stocks is not indicative of future results. The accuracy or
completeness of the information on our web site or within our reports is only as
reliable as the sources they were obtained from. The profile and opinions
expressed herein are expressed as of the date the profile is posted on site and are
subject to change without notice. No investor should assume that reliance on the
views, opinions or recommendations contained herein will produce profitable
results. SmallCapReview.com may hold positions in securities mentioned herein,
and may make purchases or sales in such securities featured on our web site or
within our reports. In order to be in full compliance with the Securities Act
of 1933, Section 17(b), SmallCapReview.com will disclose in it's
disclaimer, what, if any compensation was received for our efforts in
researching, presenting and disseminating this information to our subscriber
database and featuring the report on the SmallCapReview.com web site.
SmallCapReview.com has been compensated six hundred thousand free trading shares
of Direct View Inc. by a third party for its efforts in presenting the Direct
View Inc. profile on its web site and distributing it to its database of
subscribers. As of the date of this newsletter SmallCapReview.com has sold zero
shares. SmallCapReview.com has been compensated ten thousand dollars by a third
party for TelePlus Enterprises, three thousand dollars by a third party for
Generex Biotechnology and two thousand dollars by a third party for Biotech
Holdings for
its efforts in presenting the respective profiles on its web site and
distributing it to its database of subscribers. SmallCapReview.com may decide to purchase or sell shares on a voluntary
basis in the open market before, during or after the profiling period of this
report. Information presented on our web site and within our reports contain
"forward looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. Any statements that express or involve discussions with respect to
predictions, expectations, beliefs, plans, projections, objectives, goals,
assumptions or future events or performance are not statements of historical
fact and may be "forward looking statements." Forward looking
statements are based on expectations, estimates and projections at the time the
statements are made that involve a number of risks and uncertainties which could
cause actual results or events to differ materially from those presently
anticipated. Forward looking statements in this action may be identified through
the use of words such as ???expects??™???, ???will,??? ???anticipates,???
???estimates, ???believes,??? or that by statements indicating certain actions
???may,??? ???could,??? or ???might??? occur.
THE
READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN
ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND
CARRIES A HIGH DEGREE OF RISK.
We
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its web
site.
|
